albuterol has been researched along with Asthmatic Crisis in 90 studies
Albuterol: A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.
albuterol : A member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a beta-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).
| Excerpt | Relevance | Reference |
|---|---|---|
| "We investigated the effect of heliox-powered albuterol therapy on hospital length of stay and clinical status in children with moderate to severe status asthmaticus." | 9.14 | Helium/oxygen-driven albuterol nebulization in the management of children with status asthmaticus: a randomized, placebo-controlled trial. ( Bigham, MT; Brilli, RJ; Conway, EM; Jacobs, BR; Monaco, MA; Pettinichi, S; Wells, D; Wheeler, DS, 2010) |
| "Theophylline, when added to continuous nebulized albuterol therapy and intravenous corticosteroids, is as effective as terbutaline in treating critically ill children with status asthmaticus." | 9.11 | Theophylline versus terbutaline in treating critically ill children with status asthmaticus: a prospective, randomized, controlled trial. ( Bean, JA; Brilli, RJ; Hutson, TK; Jacobs, BR; Kenreigh, CA; Wheeler, DS, 2005) |
| "This study was conducted to determine whether intravenous theophylline, added to inhaled albuterol and intravenous methylprednisolone, provides a clinically significant benefit in the treatment of pediatric status asthmaticus." | 9.08 | Intravenous theophylline in pediatric status asthmaticus. A prospective, randomized, double-blind, placebo-controlled trial. ( Bien, JP; Bloom, MD; Evans, RL; O'Brien, KP; Specker, B, 1995) |
| "A trial was conducted of continuous nebulised salbutamol and oral once a day prednisolone in a group of 11 children with status asthmaticus (group A) and compared with a conventional protocol comprising aminophylline infusion and intravenous hydrocortisone every six hours in a matched control group (group B)." | 9.07 | Continuous nebulised salbutamol and oral once a day prednisolone in status asthmaticus. ( Kumar, L; Singh, M, 1993) |
| "In children with impending respiratory failure due to status asthmaticus, continuous nebulization of albuterol is safe and results in more rapid clinical improvement than intermittent nebulization." | 9.07 | A prospective, randomized study of continuous versus intermittent nebulized albuterol for severe status asthmaticus in children. ( Frank, J; Papo, MC; Thompson, AE, 1993) |
| "Rapid infusion of intravenous magnesium sulfate (MgSO4) was given to two young adults with impending respiratory failure caused by status asthmaticus." | 8.79 | Rapid infusion of magnesium sulfate obviates need for intubation in status asthmaticus. ( Finkelstein, JA; Schiermeyer, RP, 1994) |
| "Status asthmaticus is commonly treated in pediatric patients by using continuous albuterol, which can cause hypokalemia." | 8.12 | Hypokalemia Measurement and Management in Patients With Status Asthmaticus on Continuous Albuterol. ( Akmyradov, C; Cantu, R; Cox, C; Irby, K; Patel, K, 2022) |
| "A retrospective review of children ≥ 2 y admitted for asthma exacerbation to the PICU and step-down unit who received continuous albuterol as part of the asthma pathway during 2017-2019 was completed." | 8.12 | Safe and Effective Use of Score-Based Continuous Albuterol Therapy in a Pathway for Treatment of Pediatric Asthma Exacerbation. ( Berlinski, A; Carper, NL; Danner, NP; Lloyd, TL; Willis, LD, 2022) |
| "The re-elevation of serum lactate in status asthmaticus patient who had been administrated with the vast amount of β2-adrenergic agonist should be considered for salbutamol-induced lactic acidosis and promptly discontinued especially when there were no common potentials." | 8.02 | Salbutamol-induced lactic acidosis in status asthmaticus survivor. ( Boonkaya, S; Phoophiboon, V; Singhagowinta, P; Sriprasart, T, 2021) |
| "The primary aim of this study was to reduce duration of continuous albuterol and hospital length of stay in critically ill children with severe status asthmaticus." | 7.96 | Standardized Protocol Is Associated With a Decrease in Continuous Albuterol Use and Length of Stay in Critical Status Asthmaticus. ( Agus, MSD; Currier, D; Donelly, D; Dwyer, D; Hurlbut, J; Melendez, E; Miller, DM; Nachreiner, D; Pepin, MJ; Wong, J, 2020) |
| "Children requiring continuous albuterol for status asthmaticus can be administered magnesium sulfate outside the PICU with a low incidence of adverse events; however, among a RAS matched cohort, those who received magnesium did not experience shorter time on continuous albuterol, or hospital length of stay." | 7.88 | The effectiveness of magnesium sulfate for status asthmaticus outside the intensive care setting. ( Agasthya, N; DeSanti, RL; Hunter, K; Hussain, MJ, 2018) |
| "Children admitted to the PICU between January 2006 and December 2007 with status asthmaticus receiving high-dose continuous albuterol nebulization." | 7.81 | Effect of high-dose continuous albuterol nebulization on clinical variables in children with status asthmaticus. ( Abd-Allah, S; Bahk, TJ; Mathur, M; Phumeetham, S, 2015) |
| "Concerns have been raised regarding cardiac side effects of continuous high-dose albuterol nebulization in status asthmaticus management." | 7.81 | Diastolic hypotension in pediatric patients with asthma receiving continuous albuterol. ( Eades, S; Hashmi, SS; Mosquera, RA; Samuels, C; Wisecup, S, 2015) |
| "We prospectively examined the efficacy and safety of continuous albuterol nebulization (CAN) therapy for children diagnosed with impending respiratory failure and status asthmaticus." | 7.69 | Efficacy and safety of continuous albuterol nebulization in children with severe status asthmaticus. ( Bigos, D; Brilli, RJ; Craig, VL, 1996) |
| "We investigated the effect of heliox-powered albuterol therapy on hospital length of stay and clinical status in children with moderate to severe status asthmaticus." | 5.14 | Helium/oxygen-driven albuterol nebulization in the management of children with status asthmaticus: a randomized, placebo-controlled trial. ( Bigham, MT; Brilli, RJ; Conway, EM; Jacobs, BR; Monaco, MA; Pettinichi, S; Wells, D; Wheeler, DS, 2010) |
| "Theophylline, when added to continuous nebulized albuterol therapy and intravenous corticosteroids, is as effective as terbutaline in treating critically ill children with status asthmaticus." | 5.11 | Theophylline versus terbutaline in treating critically ill children with status asthmaticus: a prospective, randomized, controlled trial. ( Bean, JA; Brilli, RJ; Hutson, TK; Jacobs, BR; Kenreigh, CA; Wheeler, DS, 2005) |
| "This study was conducted to determine whether intravenous theophylline, added to inhaled albuterol and intravenous methylprednisolone, provides a clinically significant benefit in the treatment of pediatric status asthmaticus." | 5.08 | Intravenous theophylline in pediatric status asthmaticus. A prospective, randomized, double-blind, placebo-controlled trial. ( Bien, JP; Bloom, MD; Evans, RL; O'Brien, KP; Specker, B, 1995) |
| "A trial was conducted of continuous nebulised salbutamol and oral once a day prednisolone in a group of 11 children with status asthmaticus (group A) and compared with a conventional protocol comprising aminophylline infusion and intravenous hydrocortisone every six hours in a matched control group (group B)." | 5.07 | Continuous nebulised salbutamol and oral once a day prednisolone in status asthmaticus. ( Kumar, L; Singh, M, 1993) |
| "In children with impending respiratory failure due to status asthmaticus, continuous nebulization of albuterol is safe and results in more rapid clinical improvement than intermittent nebulization." | 5.07 | A prospective, randomized study of continuous versus intermittent nebulized albuterol for severe status asthmaticus in children. ( Frank, J; Papo, MC; Thompson, AE, 1993) |
| "Rapid infusion of intravenous magnesium sulfate (MgSO4) was given to two young adults with impending respiratory failure caused by status asthmaticus." | 4.79 | Rapid infusion of magnesium sulfate obviates need for intubation in status asthmaticus. ( Finkelstein, JA; Schiermeyer, RP, 1994) |
| " It is, further, necessary to apply these agents systemically together with theophylline, the best approach to pre-status and status asthmaticus being continuous i." | 4.77 | [Treatment of the severe asthma attack and status asthmaticus]. ( Baur, X, 1989) |
| "Status asthmaticus is commonly treated in pediatric patients by using continuous albuterol, which can cause hypokalemia." | 4.12 | Hypokalemia Measurement and Management in Patients With Status Asthmaticus on Continuous Albuterol. ( Akmyradov, C; Cantu, R; Cox, C; Irby, K; Patel, K, 2022) |
| "A retrospective review of children ≥ 2 y admitted for asthma exacerbation to the PICU and step-down unit who received continuous albuterol as part of the asthma pathway during 2017-2019 was completed." | 4.12 | Safe and Effective Use of Score-Based Continuous Albuterol Therapy in a Pathway for Treatment of Pediatric Asthma Exacerbation. ( Berlinski, A; Carper, NL; Danner, NP; Lloyd, TL; Willis, LD, 2022) |
| "We report on High Frequency Percussive Ventilation (HFPV) used along with continuous inhaled albuterol and neuromuscular blockade, as rescue therapy for a case of acute, severe asthma that was refractory to conventional treatment and conventional mechanical ventilation." | 4.02 | High frequency percussive ventilation as a rescue mode for refractory status asthmaticus - a case study. ( Albecker, D; Franklin Lewis, B; Glen Bouder, T, 2021) |
| " Using the continuous albuterol metric, predictability of the asthma scale had an area under the curve of 0." | 4.02 | Comparison of Two Assessment Tools for Hospitalized Subjects With Asthma. ( Kolaitis, IN; Nevin, MA; Palac, H; Samady, W; Schroeder, SK; Shreffler, L; Smith, CM, 2021) |
| "The re-elevation of serum lactate in status asthmaticus patient who had been administrated with the vast amount of β2-adrenergic agonist should be considered for salbutamol-induced lactic acidosis and promptly discontinued especially when there were no common potentials." | 4.02 | Salbutamol-induced lactic acidosis in status asthmaticus survivor. ( Boonkaya, S; Phoophiboon, V; Singhagowinta, P; Sriprasart, T, 2021) |
| "Implementation of an asthma protocol in the pediatric ICU did not result in significant improvements in time on continuous albuterol or hospital and pediatric ICU LOS, likely due to low adherence to the protocol." | 4.02 | Implementation of a Critical Asthma Protocol in a Pediatric ICU. ( Davey, CS; Fischer, GA; Gupta, S; Kucher, NM; S Dhaliwal, D, 2021) |
| "The primary aim of this study was to reduce duration of continuous albuterol and hospital length of stay in critically ill children with severe status asthmaticus." | 3.96 | Standardized Protocol Is Associated With a Decrease in Continuous Albuterol Use and Length of Stay in Critical Status Asthmaticus. ( Agus, MSD; Currier, D; Donelly, D; Dwyer, D; Hurlbut, J; Melendez, E; Miller, DM; Nachreiner, D; Pepin, MJ; Wong, J, 2020) |
| " Patients with a diagnosis of status asthmaticus who met criteria on continuous albuterol between September 2015 and September 2017 were included." | 3.91 | Implementing a Respiratory Therapist-Driven Continuous Albuterol Weaning Protocol in the Pediatric ICU. ( Beardsley, AL; Hole, AJ; Krupp, NL; Maue, DK; Moser, EA; Rowan, CM; Tori, AJ, 2019) |
| "The implementation of an asthma pathway was associated with decreased hospital LOS, PICU LOS, and time on continuous albuterol." | 3.91 | A Respiratory Therapist-Driven Asthma Pathway Reduced Hospital Length of Stay in the Pediatric Intensive Care Unit. ( Bartlett, KW; Gates, RM; Haynes, KE; Heath, TS; McLean, HS; Miller, AG; Rehder, KJ; Zimmerman, KO, 2019) |
| "Children requiring continuous albuterol for status asthmaticus can be administered magnesium sulfate outside the PICU with a low incidence of adverse events; however, among a RAS matched cohort, those who received magnesium did not experience shorter time on continuous albuterol, or hospital length of stay." | 3.88 | The effectiveness of magnesium sulfate for status asthmaticus outside the intensive care setting. ( Agasthya, N; DeSanti, RL; Hunter, K; Hussain, MJ, 2018) |
| "Higher albuterol dosage regimens did not result in lower admission rate or shorter length of stay in the ER, but showed similar safety profile for children with moderate to severe acute asthma." | 3.83 | Albuterol via metered-dose inhaler in children: Lower doses are effective, and higher doses are safe. ( da Silva Filho, LV; De Lalibera, IB; de Souza, AV; Muchão, FP; Rodrigues, JC; Schvartsman, C; Souza, JM; Torres, HC, 2016) |
| "Concerns have been raised regarding cardiac side effects of continuous high-dose albuterol nebulization in status asthmaticus management." | 3.81 | Diastolic hypotension in pediatric patients with asthma receiving continuous albuterol. ( Eades, S; Hashmi, SS; Mosquera, RA; Samuels, C; Wisecup, S, 2015) |
| "Children admitted to the PICU between January 2006 and December 2007 with status asthmaticus receiving high-dose continuous albuterol nebulization." | 3.81 | Effect of high-dose continuous albuterol nebulization on clinical variables in children with status asthmaticus. ( Abd-Allah, S; Bahk, TJ; Mathur, M; Phumeetham, S, 2015) |
| "To describe the design features, utilization, and outcomes of a protocol treating children with status asthmaticus with continuous albuterol in the inpatient setting." | 3.80 | Safety and effectiveness of continuous aerosolized albuterol in the non-intensive care setting. ( Fieldston, ES; Kenyon, CC; Keren, R; Luan, X; Zorc, JJ, 2014) |
| " The first, consisting of patients transported for respiratory distress having received at least 10 mg of albuterol, was studied for development of tachycardia and hypotension." | 3.79 | Diastolic hypotension is an unrecognized risk factor for β-agonist-associated myocardial injury in children with asthma. ( Arora, G; Felmet, KA; Kuch, BA; Manole, M; Orr, RA; Pitetti, RA; Saladino, RA; Sarnaik, SM, 2013) |
| "We prospectively examined the efficacy and safety of continuous albuterol nebulization (CAN) therapy for children diagnosed with impending respiratory failure and status asthmaticus." | 3.69 | Efficacy and safety of continuous albuterol nebulization in children with severe status asthmaticus. ( Bigos, D; Brilli, RJ; Craig, VL, 1996) |
| "Hypokalemia and lactic acidosis developed following correction of respiratory acidosis in a 5-year-old child who presented with respiratory failure secondary to severe asthma and treated with theophylline, inhaled albuterol, and parenteral methylprednisolone." | 3.67 | Therapy of acute bronchospasm. Complicated by lactic acidosis and hypokalemia. ( Assadi, FK, 1989) |
| "Co-administration of intravenous albuterol and theophylline resulted in increased theophylline clearance in a child with severe asthma." | 3.67 | Enhancement of theophylline clearance by intravenous albuterol. ( Amirav, I; Amitai, Y; Avital, A; Godfrey, S, 1988) |
| " Pharmacokinetic-pharmacodynamic (PKPD) models to guide paediatric dosing are lacking." | 3.30 | Optimising intravenous salbutamol in children: a phase 2 study. ( Anderson, BJ; Kloprogge, F; Pan, S; Ramnarayan, P; Sheng, Y; Standing, JF; Walsh, S, 2023) |
| "To compare the efficacy of nebulised salbutamol alone and in combination with ipratropium bromide in acute severe asthma in children." | 2.82 | Response to nebulized salbutamol versus combination with ipratropium bromide in children with acute severe asthma. ( Ahmed Khan, KM; Bai, C; Gowa, MA; Memon, BN; Parkash, A, 2016) |
| "5 mg albuterol by jet nebulization in a dosing schedule determined by the ACA phase." | 2.70 | Ipratropium bromide plus nebulized albuterol for the treatment of hospitalized children with acute asthma. ( Craven, D; Golonka, G; Kercsmar, CM; Moore, S; Myers, TR; O'riordan, MA, 2001) |
| "In this article the pathophysiology and treatment of status asthmaticus is discussed, and the literature regarding second-line treatments is critically assessed to apply an evidence basis to the treatment of this severe disease." | 2.49 | Pediatric status asthmaticus. ( Carroll, CL; Sala, KA, 2013) |
| "Patients admitted for asthma or COPD exacerbations, doctors, and nurses in a university-affiliated hospital were surveyed from 1 April 2021 to 30 September 2021 regarding their views on the effectiveness, ease of use, preparation and administration, side effects, and infection risk of the two administration methods." | 1.91 | Nebulizer versus metered dose inhaler with space chamber (MDI spacer) for acute asthma and chronic obstructive pulmonary disease exacerbation: attitudes of patients and healthcare providers in the COVID-19 era. ( Alsuwaigh, R; Binte Mohd Noor, N; Cao, Y; Chen, H; Li, XL; Liew, J; Mohamed Noor, SB; Puan, Y; Tay, TR; Ye, H; Yii, A, 2023) |
| "Intravenous salbutamol is used to treat children with refractory status asthmaticus, however insufficient pharmacokinetic data are available to guide initial and subsequent dosing recommendations for its intravenous use." | 1.56 | Population Pharmacokinetics of Intravenous Salbutamol in Children with Refractory Status Asthmaticus. ( Boehmer, ALM; Boeschoten, SA; Buysse, CMP; de Hoog, M; de Wildt, SN; de Winter, BCM; Knibbe, CAJ; Koch, BCP; Koninckx, M; Plötz, FB; Vaessen-Verberne, AA; van der Nagel, BCH; Verhallen, JT; Vet, NJ, 2020) |
| " The time to q2h dosing from initiation of CAN was compared between the baseline and SCAMP cohorts." | 1.46 | A Critical Asthma Standardized Clinical and Management Plan Reduces Duration of Critical Asthma Therapy. ( Agus, MS; Graham, DA; Melendez, E; Wong, J, 2017) |
| "The myopathy of status asthmaticus is not a homogeneous clinicopathological entity." | 1.29 | Acute myopathy in status asthmaticus. ( Blackie, JD; Gibson, P; Murree-Allen, K; Saul, WP, 1993) |
| "Status asthmaticus is one of the most common conditions for which children seek care in a pediatric emergency department." | 1.29 | Adenosine in the termination of albuterol-induced supraventricular tachycardia. ( Cook, P; Cook, RT; Scarfone, RJ, 1994) |
| " No patient required escalation of dosage or additional intervention such as intravenous beta-agonist therapy or mechanical ventilation." | 1.29 | Low-dose beta-agonist continuous nebulization therapy for status asthmaticus in children. ( Eid, NS; Montgomery, VL, 1994) |
| "Tremor has been found to be a limiting side effect with the oral or the inhaled forms." | 1.28 | An exaggerated response to beta-adrenergics. ( Lerner, C; Ozog, D, 1989) |
| " This study was undertaken to compare the clinical effectiveness and toxicity of these two drugs and to try to establish dosage schedules of inhaled salbutamol with spacer in the treatment of acute asthma." | 1.27 | [Subcutaneous adrenaline versus inhaled salbutamol in the treatment of childhood asthmatic crisis]. ( Bonal de Falgas, J; Farré Riba, R; Ferrés Mataró, J; Juliá Brugues, A; Mangues Bafalluy, MA, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (16.67) | 18.7374 |
| 1990's | 19 (21.11) | 18.2507 |
| 2000's | 18 (20.00) | 29.6817 |
| 2010's | 24 (26.67) | 24.3611 |
| 2020's | 14 (15.56) | 2.80 |
| Authors | Studies |
|---|---|
| Cox, C | 1 |
| Patel, K | 1 |
| Cantu, R | 1 |
| Akmyradov, C | 1 |
| Irby, K | 1 |
| Alsuwaigh, R | 1 |
| Cao, Y | 1 |
| Puan, Y | 1 |
| Yii, A | 1 |
| Mohamed Noor, SB | 1 |
| Ye, H | 1 |
| Chen, H | 1 |
| Li, XL | 1 |
| Binte Mohd Noor, N | 1 |
| Liew, J | 1 |
| Tay, TR | 1 |
| Boeschoten, SA | 2 |
| Buysse, CMP | 2 |
| de Winter, BCM | 2 |
| van Rosmalen, J | 1 |
| de Jongste, JC | 1 |
| de Jonge, RC | 1 |
| Heisterkamp, SGJ | 1 |
| van Woensel, JB | 1 |
| Kneyber, MCJ | 1 |
| van Zwol, A | 1 |
| Boehmer, ALM | 2 |
| de Hoog, M | 3 |
| Willis, LD | 1 |
| Danner, NP | 1 |
| Lloyd, TL | 1 |
| Carper, NL | 1 |
| Berlinski, A | 1 |
| Walsh, S | 1 |
| Pan, S | 1 |
| Sheng, Y | 1 |
| Kloprogge, F | 1 |
| Standing, JF | 1 |
| Anderson, BJ | 1 |
| Ramnarayan, P | 1 |
| Vet, NJ | 1 |
| Koninckx, M | 1 |
| Verhallen, JT | 1 |
| Plötz, FB | 1 |
| Vaessen-Verberne, AA | 1 |
| van der Nagel, BCH | 1 |
| Knibbe, CAJ | 1 |
| de Wildt, SN | 1 |
| Koch, BCP | 1 |
| Albecker, D | 1 |
| Glen Bouder, T | 1 |
| Franklin Lewis, B | 1 |
| Agnihotri, NT | 1 |
| Saltoun, C | 1 |
| Boeschoten, S | 1 |
| Kneyber, M | 1 |
| Merkus, P | 1 |
| Boehmer, A | 1 |
| Buysse, C | 1 |
| Melendez, E | 2 |
| Dwyer, D | 1 |
| Donelly, D | 1 |
| Currier, D | 1 |
| Nachreiner, D | 1 |
| Miller, DM | 1 |
| Hurlbut, J | 1 |
| Pepin, MJ | 1 |
| Agus, MSD | 1 |
| Wong, J | 2 |
| Carroll, CL | 2 |
| Schroeder, SK | 1 |
| Samady, W | 1 |
| Kolaitis, IN | 1 |
| Smith, CM | 1 |
| Palac, H | 1 |
| Shreffler, L | 1 |
| Nevin, MA | 1 |
| Phoophiboon, V | 1 |
| Singhagowinta, P | 1 |
| Boonkaya, S | 1 |
| Sriprasart, T | 1 |
| Kucher, NM | 1 |
| S Dhaliwal, D | 1 |
| Fischer, GA | 1 |
| Davey, CS | 1 |
| Gupta, S | 1 |
| Bonadio, W | 1 |
| DeSanti, RL | 1 |
| Agasthya, N | 1 |
| Hunter, K | 1 |
| Hussain, MJ | 1 |
| Brennan, S | 1 |
| Lowrie, L | 1 |
| Wooldridge, J | 1 |
| Bartman, T | 1 |
| Brilli, RJ | 4 |
| Kane, JM | 1 |
| Phillips, M | 1 |
| Grunwell, JR | 1 |
| Travers, C | 1 |
| Fitzpatrick, AM | 1 |
| Maue, DK | 1 |
| Tori, AJ | 1 |
| Beardsley, AL | 1 |
| Krupp, NL | 1 |
| Hole, AJ | 1 |
| Moser, EA | 1 |
| Rowan, CM | 1 |
| Miller, AG | 2 |
| Haynes, KE | 1 |
| Gates, RM | 1 |
| Zimmerman, KO | 1 |
| Heath, TS | 1 |
| Bartlett, KW | 1 |
| McLean, HS | 1 |
| Rehder, KJ | 1 |
| Sala, KA | 1 |
| Sarnaik, SM | 1 |
| Saladino, RA | 1 |
| Manole, M | 1 |
| Pitetti, RA | 1 |
| Arora, G | 1 |
| Kuch, BA | 1 |
| Orr, RA | 1 |
| Felmet, KA | 1 |
| Kenyon, CC | 1 |
| Fieldston, ES | 1 |
| Luan, X | 1 |
| Keren, R | 1 |
| Zorc, JJ | 1 |
| Phumeetham, S | 1 |
| Bahk, TJ | 1 |
| Abd-Allah, S | 1 |
| Mathur, M | 1 |
| Burns, J | 1 |
| Wisecup, S | 1 |
| Eades, S | 1 |
| Hashmi, SS | 1 |
| Samuels, C | 1 |
| Mosquera, RA | 1 |
| Breslin, ME | 1 |
| Pineda, LC | 1 |
| Fox, JW | 1 |
| Memon, BN | 1 |
| Parkash, A | 1 |
| Ahmed Khan, KM | 1 |
| Gowa, MA | 1 |
| Bai, C | 1 |
| Muchão, FP | 1 |
| Souza, JM | 1 |
| Torres, HC | 1 |
| De Lalibera, IB | 1 |
| de Souza, AV | 1 |
| Rodrigues, JC | 1 |
| Schvartsman, C | 1 |
| da Silva Filho, LV | 1 |
| Agus, MS | 1 |
| Graham, DA | 1 |
| Singh, AK | 1 |
| Gaur, S | 1 |
| Kumar, R | 1 |
| Papiris, SA | 1 |
| Manali, ED | 1 |
| Kolilekas, L | 1 |
| Triantafillidou, C | 1 |
| Tsangaris, I | 1 |
| Gallegos-Solórzano, MC | 1 |
| Pérez-Padilla, R | 1 |
| Hernández-Zenteno, RJ | 1 |
| Bigham, MT | 1 |
| Jacobs, BR | 2 |
| Monaco, MA | 1 |
| Wells, D | 1 |
| Conway, EM | 1 |
| Pettinichi, S | 1 |
| Wheeler, DS | 2 |
| Stanojevic, DA | 1 |
| Alla, VM | 1 |
| Lynch, JD | 1 |
| Hunter, CB | 1 |
| Grover, S | 1 |
| Jindal, A | 1 |
| Bansal, A | 1 |
| Singhi, SC | 1 |
| Bhogal, SK | 1 |
| McGillivray, D | 1 |
| Bourbeau, J | 1 |
| Benedetti, A | 1 |
| Bartlett, S | 1 |
| Ducharme, FM | 1 |
| Saxena, R | 1 |
| Marais, G | 1 |
| Karwat, K | 1 |
| Higgins, JC | 1 |
| Jacobson, GA | 1 |
| Chong, FV | 1 |
| Wood-Baker, R | 1 |
| Biswas, AK | 1 |
| Fruedenthal, WC | 1 |
| Kenreigh, CA | 1 |
| Bean, JA | 1 |
| Hutson, TK | 1 |
| Udy, A | 1 |
| Wechsler, ME | 1 |
| Shepard, JA | 1 |
| Mark, EJ | 1 |
| Bogie, AL | 1 |
| Towne, D | 1 |
| Luckett, PM | 1 |
| Abramo, TJ | 1 |
| Wiebe, RA | 1 |
| González de Olano, D | 1 |
| Trujillo Trujillo, MJ | 1 |
| Santos Magadán, S | 1 |
| Menéndez-Baltanás, A | 1 |
| Gandolfo Cano, M | 1 |
| Ariz Muñoz, S | 1 |
| Sanz Larruga, ML | 1 |
| González-Mancebo, E | 1 |
| Bohn, D | 1 |
| Kalloghlian, A | 1 |
| Jenkins, J | 1 |
| Edmonds, J | 1 |
| Barker, G | 1 |
| Bien, JP | 1 |
| Bloom, MD | 1 |
| Evans, RL | 1 |
| Specker, B | 1 |
| O'Brien, KP | 1 |
| Blackie, JD | 1 |
| Gibson, P | 1 |
| Murree-Allen, K | 1 |
| Saul, WP | 1 |
| Cook, P | 1 |
| Scarfone, RJ | 1 |
| Cook, RT | 1 |
| Bellomo, R | 1 |
| McLaughlin, P | 1 |
| Tai, E | 1 |
| Parkin, G | 1 |
| Schiermeyer, RP | 1 |
| Finkelstein, JA | 1 |
| Montgomery, VL | 1 |
| Eid, NS | 1 |
| Singh, M | 1 |
| Kumar, L | 1 |
| Papo, MC | 1 |
| Frank, J | 1 |
| Thompson, AE | 1 |
| Idris, AH | 1 |
| McDermott, MF | 1 |
| Raucci, JC | 1 |
| Morrabel, A | 1 |
| McGorray, S | 1 |
| Hendeles, L | 1 |
| Craig, VL | 1 |
| Bigos, D | 1 |
| Sangla, I | 1 |
| Pouget, J | 1 |
| Pellissier, JF | 1 |
| Serratrice, G | 1 |
| Ohta, K | 1 |
| Nakagome, K | 1 |
| Akiyama, K | 1 |
| Sano, Y | 1 |
| Matsumura, Y | 1 |
| Kudo, S | 1 |
| Yamada, K | 1 |
| Mano, K | 1 |
| Kabe, J | 1 |
| Miyashita, H | 1 |
| Bonillo Perales, A | 1 |
| Romero González, J | 1 |
| Picazo Angelín, B | 1 |
| Tapia Ceballos, L | 1 |
| Romero Sánchez, J | 1 |
| Martínez Marín, MI | 1 |
| Caussade, D | 1 |
| Sanchez, P | 1 |
| Didier, A | 1 |
| Berjaud, J | 1 |
| Ducassé, JL | 1 |
| Teeter, JG | 1 |
| Bisgaard, H | 1 |
| Lee, T | 1 |
| Dennis, S | 1 |
| Benito Fernández , J | 1 |
| Mintegui Raso , S | 1 |
| Sánchez Echaniz , J | 1 |
| Vázquez Ronco , MA | 1 |
| Pijoan Zubizarreta , JI | 1 |
| Craven, D | 1 |
| Kercsmar, CM | 1 |
| Myers, TR | 1 |
| O'riordan, MA | 1 |
| Golonka, G | 1 |
| Moore, S | 1 |
| Panicker, J | 1 |
| Sethi, GR | 1 |
| Sehgal, V | 1 |
| Rebrov, AP | 1 |
| Karoli, NA | 1 |
| Timsit, S | 1 |
| Sannier, N | 1 |
| Bocquet, N | 1 |
| Cojocaru, B | 1 |
| Wille, C | 1 |
| Boursiquot, C | 1 |
| Garel, D | 1 |
| Marcombes, F | 1 |
| Chéron, G | 1 |
| Quijada, C | 1 |
| Galleguillos, F | 1 |
| Niggemann, B | 1 |
| Wahn, U | 1 |
| Asher, MI | 1 |
| Douglas, C | 1 |
| Airy, M | 1 |
| Andrews, D | 1 |
| Trenholme, A | 1 |
| Voss, KR | 1 |
| Willsie-Ediger, SK | 1 |
| Pyszczynski, DR | 1 |
| Nelson, KA | 1 |
| Ozog, D | 1 |
| Lerner, C | 1 |
| Baur, X | 1 |
| Assadi, FK | 1 |
| Sheehan, GJ | 1 |
| Kutzner, MR | 1 |
| Chin, WD | 1 |
| Morley, TF | 1 |
| Marozsan, E | 1 |
| Zappasodi, SJ | 1 |
| Gordon, R | 1 |
| Griesback, R | 1 |
| Giudice, JC | 1 |
| Beauvoir, C | 1 |
| Sissman, J | 1 |
| Pin, I | 1 |
| Pincemaille, O | 1 |
| Jouk, PS | 1 |
| Bost, M | 1 |
| Amirav, I | 1 |
| Amitai, Y | 1 |
| Avital, A | 1 |
| Godfrey, S | 1 |
| Schiavi, EA | 1 |
| Ferrés Mataró, J | 1 |
| Mangues Bafalluy, MA | 1 |
| Farré Riba, R | 1 |
| Juliá Brugues, A | 1 |
| Bonal de Falgas, J | 1 |
| Giner, MT | 1 |
| Nevot, S | 1 |
| Sierra, JI | 1 |
| Plaza, A | 1 |
| Coma, G | 1 |
| Youssef, W | 1 |
| Carson, JW | 1 |
| Taylor, MR | 1 |
| Claybo, R | 1 |
| Gauthier, M | 1 |
| Lacroix, J | 1 |
| Lamarre, A | 1 |
| Rousseau, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Increasing Doses of Inhaled Albuterol Administered by Metered Dose Inhalers in Children With Acute Wheezing Episodes[NCT01323010] | 119 participants (Actual) | Interventional | 2011-09-30 | Completed | |||
| A Prospective Open Randomized Clinical Trial Comparing Bilevel Positive Airway Pressure (BiPAP) Therapy Against Standard Therapy for Children Hospitalized With an Acute Exacerbation of Asthma Unresponsive to Inhaled Bronchodilators.[NCT02347462] | 0 participants (Actual) | Interventional | 2015-04-30 | Withdrawn (stopped due to we were not able to work through the logistics of the study to support enrolment in ER) | |||
| A Prospective Open Randomized Clinical Trial of Non-invasive Ventilation Versus Standard Therapy for Children Hospitalized With an Acute Exacerbation of Asthma.[NCT03296579] | 100 participants (Anticipated) | Interventional | 2018-06-30 | Not yet recruiting | |||
| A Phase I, Single Center, Placebo-Controlled, Blinded Pilot Study of Ipratropium Bromide in Children Admitted to the Intensive Care Unit With Status Asthmaticus[NCT02872597] | Phase 1 | 30 participants (Actual) | Interventional | 2016-09-05 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Admission rates in patients with and without any of the following viruses detected by PCR in nasal lavage samples: Adenovirus; Bocavirus; Coronavirus; Enterovirus (Echovirus); Influenza (A H3N2, A H1N1/2009, B and C); Metapneumovirus (subtypes A and B); Parainfluenza 1, 2, 3 and 4 (subtypes A and B); Rhinovirus; Respiratory Syncytial Virus type A and Respiratory Syncytial Virus type B. (NCT01323010)
Timeframe: at discharge or admission (up to 4 hours post treatment, minimum 1 hour, maximum 4 hours post treatment)
| Intervention | percentage of participants (Number) |
|---|---|
| Virus Detected | 12.3 |
| No Virus Detected | 22.7 |
Admission rates in patients with and without rhinovirus detected by PCR in nasal lavage samples. (NCT01323010)
Timeframe: at discharge or admission (up to 4 hours post treatment, minimum 1 hour, maximum 4 hours post treatment)
| Intervention | percentage of participants (Number) |
|---|---|
| Rhinovirus Detected | 10.2 |
| No Rhinovirus Detected | 20.6 |
Admission rates in patients with the Arg16Gly polymorphisms of the beta-2 adrenergic receptor (Arg16Gly, Arg16Arg and Gly16Gly genotypes). (NCT01323010)
Timeframe: at discharge or admission (up to 4 hours post treatment, minimum 1 hour, maximum 4 hours post treatment)
| Intervention | participants (Number) |
|---|---|
| Arg16Gly Patients | 1 |
| Gly16Gly Patients | 1 |
| Arg16Arg Patients | 7 |
Albuterol determination in the plasma was carried out at at discharge or hospital admission (up to 4 hours post treatment), dosage was accomplished by High Performance Liquid Chromatography. (NCT01323010)
Timeframe: at discharge or admission (up to 4 hours post treatment, minimum 1 hour, maximum 4 hours post treatment)
| Intervention | ng/ml (Median) |
|---|---|
| Albuterol - Higher Dose (Experimental) | 2.57 |
| Albuterol - Lower Dose (Control) | 1.08 |
"Change in the Pediatric Respiratory Assessment Measure (PRAM) score one hour post-treatment in comparison with baseline.~The PRAM score is used to assess the severity of asthma attacks, it ranges from 0 to 15, and the higher the score, the greater the severity of the attack.~We calculated the difference between the PRAM score measured one hour post treatment and the PRAM score at baseline (PRAM score 1 hour - PRAM score baseline).~The larger the absolute value of the difference, the better the outcome (e.g., a difference of -4 indicates a better outcome that a difference of -2).~minimum value of the difference (Albuterol - Higher Dose, experimental group): -8 maximum value of the difference (Albuterol - Higher Dose, experimental group): 0~minimum value of the difference (Albuterol - Lower Dose, control group): -8 maximum value of the difference (Albuterol - Lower Dose, control group): 0" (NCT01323010)
Timeframe: One hour post-treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Albuterol - Higher Dose (Experimental) | -3 |
| Albuterol - Lower Dose (Control) | -4 |
Change in pulse oximetry one hour post-treatment in comparison with baseline (NCT01323010)
Timeframe: One hour post-treatment in comparison with baseline
| Intervention | percentage of oxygen saturation (Mean) |
|---|---|
| Albuterol - Higher Dose (Experimental) | 1.54 |
| Albuterol - Lower Dose (Control) | 1.39 |
Changes in bicarbonate serum levels at discharge or hospital admission (up to 4 hours post treatment) in comparison with baseline. (NCT01323010)
Timeframe: at discharge or admission (up to 4 hours post treatment, minimum 1 hour, maximum 4 hours post treatment) in comparison with baseline.
| Intervention | mmol/L (Mean) |
|---|---|
| Albuterol - Higher Dose (Experimental) | -1.75 |
| Albuterol - Lower Dose (Control) | -1.44 |
Changes in glucose serum levels at discharge or hospital admission (up to 4 hours post treatment) in comparison with baseline. (NCT01323010)
Timeframe: at discharge or admission (up to 4 hours post treatment, minimum 1 hour, maximum 4 hours post treatment) in comparison with baseline.
| Intervention | mg/dL (Mean) |
|---|---|
| Albuterol - Higher Dose (Experimental) | 34.73 |
| Albuterol - Lower Dose (Control) | 22.90 |
Change in heart rate one hour post-treatment in comparison with baseline. (NCT01323010)
Timeframe: One hour post-treatment in comparison with baseline
| Intervention | beats per minute (Mean) |
|---|---|
| Albuterol - Higher Dose (Experimental) | 1.75 |
| Albuterol - Lower Dose (Control) | -1.47 |
Changes in heart rate at discharge or hospital admission (up to 4 hours post treatment) in comparison with baseline. (NCT01323010)
Timeframe: at discharge or admission (up to 4 hours post treatment, minimum 1 hour, maximum 4 hours post treatment)
| Intervention | beats per minute (Mean) |
|---|---|
| Albuterol - Higher Dose (Experimental) | -0.263 |
| Albuterol - Lower Dose (Control) | -0.65 |
Changes in potassium serum levels at discharge or hospital admission (up to 4 hours post treatment) in comparison with baseline. (NCT01323010)
Timeframe: at discharge or admission (up to 4 hours post treatment, minimum 1 hour, maximum 4 hours post treatment) in comparison with baseline.
| Intervention | mEq/L (Mean) |
|---|---|
| Albuterol - Higher Dose (Experimental) | -0.38 |
| Albuterol - Lower Dose (Control) | -0.59 |
"Change in the Pediatric Respiratory Assessment Measure (PRAM) score at discharge or hospital admission (up to 4 hours post treatment) in comparison with baseline.~The PRAM score is used to assess the severity of asthma attacks, it ranges from 0 to 15, and the higher the score, the greater the severity of the attack.~We calculated the difference between the PRAM score measured at discharge or admission and the PRAM score at baseline (PRAM score discharge or admission - PRAM score baseline).~The larger the absolute value of the difference, the better the outcome (e.g., a difference of -4 indicates a better outcome that a difference of -2).~minimum value of the difference (Albuterol - Higher Dose, experimental group): -9 maximum value of the difference (Albuterol - Higher Dose, experimental group): 0~minimum value of the difference (Albuterol - Lower Dose, control group): -9 maximum value of the difference (Albuterol - Lower Dose, control group): 1" (NCT01323010)
Timeframe: at discharge or admission (up to 4 hours post treatment, minimum 1 hour, maximum 4 hours post treatment) in comparison with baseline.
| Intervention | units on a scale (Median) |
|---|---|
| Albuterol - Higher Dose (Experimental) | -4.5 |
| Albuterol - Lower Dose (Control) | -5 |
Changes in pulse oximetry at discharge or hospital admission (up to 4 hours post treatment) in comparison with baseline. (NCT01323010)
Timeframe: at discharge or admission (up to 4 hours post treatment, minimum 1 hour, maximum 4 hours post treatment) in comparison with baseline.
| Intervention | percentage of oxygen saturation (Mean) |
|---|---|
| Albuterol - Higher Dose (Experimental) | 2.14 |
| Albuterol - Lower Dose (Control) | 1.59 |
Change in respiratory rate one hour post-treatment in comparison with baseline. (NCT01323010)
Timeframe: One hour post-treatment in comparison with baseline
| Intervention | breaths per minute (Mean) |
|---|---|
| Albuterol - Higher Dose (Experimental) | -2.08 |
| Albuterol - Lower Dose (Control) | -4.31 |
Changes in respiratory rate at discharge or hospital admission (up to 4 hours post treatment) in comparison with baseline. (NCT01323010)
Timeframe: at discharge or admission (up to 4 hours post treatment, minimum 1 hour, maximum 4 hours post treatment) in comparison with baseline.
| Intervention | breaths per minute (Mean) |
|---|---|
| Albuterol - Higher Dose (Experimental) | -2.92 |
| Albuterol - Lower Dose (Control) | -5.76 |
Electrocardiogram performed at baseline (NCT01323010)
Timeframe: at baseline
| Intervention | participants with ECG abnormalities (Number) |
|---|---|
| Albuterol - Higher Dose (Experimental) | 0 |
| Albuterol - Lower Dose (Control) | 0 |
Electrocardiogram at discharge or hospital admission to identify possible rhythm disturbances. (NCT01323010)
Timeframe: at discharge or admission (up to 4 hours post treatment, minimum 1 hour, maximum 4 hours post treatment)
| Intervention | participants with ECG abnormalities (Number) |
|---|---|
| Experimental Group | 0 |
| Control Group | 0 |
Electrocardiogram one hour post-treatment to identify possible rhythm disturbances. (NCT01323010)
Timeframe: One hour post-treatment
| Intervention | participants with ECG abnormalities (Number) |
|---|---|
| Albuterol - Higher Dose (Experimental) | 0 |
| Albuterol - Lower Dose (Control) | 0 |
Change in FEV1 one hour post-treatment in comparison with baseline. Spirometry was performed only in subjects older than 6 years and who could perform the maneuver properly. (NCT01323010)
Timeframe: One hour post-treatment in comparison with baseline
| Intervention | percentage of predicted (Mean) |
|---|---|
| Albuterol - Higher Dose (Experimental) | 14.67 |
| Albuterol - Lower Dose (Control) | 11.3 |
Hospital admission was defined as the need to stay in the emergency room for more than 4 hours, due to the failure to meet the discharge criteria (PRAM score ≤ 3 and pulse oximetry, ≥ 92%) (NCT01323010)
Timeframe: Starting at 4 hours post-treatment
| Intervention | participants (Number) |
|---|---|
| Albuterol - Higher Dose (Experimental) | 11 |
| Albuterol - Lower Dose (Control) | 8 |
lengths of stay in the emergency room for discharged patients (NCT01323010)
Timeframe: one to four hours
| Intervention | hours (Median) |
|---|---|
| Albuterol - Higher Dose (Experimental) | 1.50 |
| Albuterol - Lower Dose (Control) | 1.40 |
The need for additional therapies such as magnesium sulphate or intravenous albuterol were recorded (NCT01323010)
Timeframe: at discharge or admission (up to 4 hours post treatment, minimum 1 hour, maximum 4 hours post treatment)
| Intervention | participants (Number) |
|---|---|
| Albuterol - Higher Dose (Experimental) | 0 |
| Albuterol - Lower Dose (Control) | 0 |
8 reviews available for albuterol and Asthmatic Crisis
| Article | Year |
|---|---|
Acute severe asthma (status asthmaticus).
Topics: Adrenal Cortex Hormones; Albuterol; Drug Therapy, Combination; Emergency Medicine; Forced Expiratory | 2019 |
Pediatric status asthmaticus.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Airway Obstruction; Albuterol; Anti-Asthmatic A | 2013 |
The 'crashing asthmatic.'.
Topics: Adrenergic beta-Agonists; Albuterol; Bronchodilator Agents; Furans; Glucocorticoids; Humans; Intubat | 2003 |
Rapid infusion of magnesium sulfate obviates need for intubation in status asthmaticus.
Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Drug Therapy, Combination; Emergency Servi | 1994 |
Long-acting beta(2)-agonists in management of childhood asthma: A critical review of the literature.
Topics: Administration, Topical; Adrenergic beta-Agonists; Albuterol; Anti-Inflammatory Agents; Asthma; Asth | 2000 |
[Use of glucocorticosteroids in asthmatic conditions (review)].
Topics: Acute Disease; Adrenergic beta-Agonists; Adult; Albuterol; Algorithms; Asthma; Bronchodilator Agents | 2001 |
[Therapy of status asthmaticus in childhood. A current review].
Topics: Administration, Inhalation; Albuterol; Child; Child, Preschool; Combined Modality Therapy; Cromolyn | 1991 |
[Treatment of the severe asthma attack and status asthmaticus].
Topics: Airway Resistance; Albuterol; Asthma; Drug Therapy, Combination; Fenoterol; Humans; Prednisolone; St | 1989 |
20 trials available for albuterol and Asthmatic Crisis
| Article | Year |
|---|---|
Efficacy of a loading dose of IV salbutamol in children with severe acute asthma admitted to a PICU: a randomized controlled trial.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Child; Humans; Intensive Care | 2022 |
Optimising intravenous salbutamol in children: a phase 2 study.
Topics: Administration, Intravenous; Albuterol; Asthma; Child; Emergency Service, Hospital; Humans; Prospect | 2023 |
Response to nebulized salbutamol versus combination with ipratropium bromide in children with acute severe asthma.
Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Pres | 2016 |
A randomized controlled trial of intravenous magnesium sulphate as an adjunct to standard therapy in acute severe asthma.
Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Drug Therapy, Combination; Dyspnea; Female | 2008 |
Usefulness of inhaled magnesium sulfate in the coadjuvant management of severe asthma crisis in an emergency department.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Albuterol; Anti-Asthmatic Agents; Bronch | 2010 |
Helium/oxygen-driven albuterol nebulization in the management of children with status asthmaticus: a randomized, placebo-controlled trial.
Topics: Adolescent; Albuterol; Bronchodilator Agents; Child; Child, Preschool; Female; Helium; Humans; Male; | 2010 |
Early administration of systemic corticosteroids reduces hospital admission rates for children with moderate and severe asthma exacerbation.
Topics: Adolescent; Adrenal Cortex Hormones; Albuterol; Bronchodilator Agents; Child; Child, Preschool; Crit | 2012 |
Theophylline versus terbutaline in treating critically ill children with status asthmaticus: a prospective, randomized, controlled trial.
Topics: Adolescent; Albuterol; Bronchodilator Agents; Child; Child, Preschool; Critical Illness; Double-Blin | 2005 |
Comparison of intravenous terbutaline versus normal saline in pediatric patients on continuous high-dose nebulized albuterol for status asthmaticus.
Topics: Administration, Inhalation; Adolescent; Albuterol; Bronchodilator Agents; Child; Child, Preschool; D | 2007 |
Intravenous theophylline in pediatric status asthmaticus. A prospective, randomized, double-blind, placebo-controlled trial.
Topics: Administration, Inhalation; Age Factors; Albuterol; Bronchodilator Agents; Child; Child, Preschool; | 1995 |
Continuous nebulised salbutamol and oral once a day prednisolone in status asthmaticus.
Topics: Administration, Inhalation; Administration, Oral; Albuterol; Child; Drug Administration Schedule; Dr | 1993 |
A prospective, randomized study of continuous versus intermittent nebulized albuterol for severe status asthmaticus in children.
Topics: Adolescent; Albuterol; Child; Child, Preschool; Cost-Benefit Analysis; Female; Humans; Infant; Inten | 1993 |
Emergency department treatment of severe asthma. Metered-dose inhaler plus holding chamber is equivalent in effectiveness to nebulizer.
Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Child; Double-Blind Method; Emergencies; E | 1993 |
Aminophylline is effective on acute exacerbations of asthma in adults--objective improvements in peak flow, spirogram, arterial blood gas measurements and lung sounds.
Topics: Albuterol; Aminophylline; Blood Gas Analysis; Female; Forced Expiratory Volume; Humans; Male; Middle | 1996 |
[Efficacy of early administration of nebulized ipratropium bromide in children with asthmatic crisis].
Topics: Administration, Inhalation; Adolescent; Albuterol; Bronchodilator Agents; Child; Child, Preschool; D | 2000 |
Ipratropium bromide plus nebulized albuterol for the treatment of hospitalized children with acute asthma.
Topics: Acute Disease; Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Age Factors; Albute | 2001 |
Comparative efficiency of commercial and improvised spacer device in acute bronchial asthma.
Topics: Administration, Inhalation; Albuterol; Asthma; Child; Child, Preschool; Dose-Response Relationship, | 2001 |
[Benefits of ipratropium bromide in the management of asthmatic crises in the emergency department].
Topics: Adolescent; Adrenergic beta-Agonists; Albuterol; Bronchodilator Agents; Chi-Square Distribution; Chi | 2002 |
[Alternative treatment for acute asthmatic crisis].
Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Double-Blind Method; Female; Humans; Injec | 1992 |
Effects of chest physical therapy on lung function in children recovering from acute severe asthma.
Topics: Adolescent; Albuterol; Breathing Exercises; Child; Female; Humans; Lung; Male; Physical Therapy Moda | 1990 |
62 other studies available for albuterol and Asthmatic Crisis
| Article | Year |
|---|---|
Hypokalemia Measurement and Management in Patients With Status Asthmaticus on Continuous Albuterol.
Topics: Albuterol; Bronchodilator Agents; Child; Humans; Hypokalemia; Retrospective Studies; Status Asthmati | 2022 |
Nebulizer versus metered dose inhaler with space chamber (MDI spacer) for acute asthma and chronic obstructive pulmonary disease exacerbation: attitudes of patients and healthcare providers in the COVID-19 era.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Attitude of Health Personnel; Bronchodilator A | 2023 |
Safe and Effective Use of Score-Based Continuous Albuterol Therapy in a Pathway for Treatment of Pediatric Asthma Exacerbation.
Topics: Albuterol; Asthma; Bronchodilator Agents; Child; Female; Humans; Length of Stay; Male; Status Asthma | 2022 |
Population Pharmacokinetics of Intravenous Salbutamol in Children with Refractory Status Asthmaticus.
Topics: Administration, Intravenous; Adolescent; Adrenergic beta-2 Receptor Agonists; Albuterol; Child; Chil | 2020 |
High frequency percussive ventilation as a rescue mode for refractory status asthmaticus - a case study.
Topics: Administration, Inhalation; Adult; Albuterol; Blood Gas Analysis; Bronchodilator Agents; Female; Hig | 2021 |
Current practices in children with severe acute asthma across European PICUs: an ESPNIC survey.
Topics: Albuterol; Bronchodilator Agents; Child; Cross-Sectional Studies; Europe; Humans; Intensive Care Uni | 2020 |
Standardized Protocol Is Associated With a Decrease in Continuous Albuterol Use and Length of Stay in Critical Status Asthmaticus.
Topics: Albuterol; Bronchodilator Agents; Child; Child, Preschool; Female; Humans; Length of Stay; Prospecti | 2020 |
SCAMP-ering Toward Improved Quality of Care in Children With Status Asthmaticus.
Topics: Albuterol; Child; Humans; Length of Stay; Longitudinal Studies; Retrospective Studies; Status Asthma | 2020 |
Comparison of Two Assessment Tools for Hospitalized Subjects With Asthma.
Topics: Albuterol; Asthma; Child; Hospitalization; Humans; Prospective Studies; Status Asthmaticus | 2021 |
Salbutamol-induced lactic acidosis in status asthmaticus survivor.
Topics: Acidosis; Acidosis, Lactic; Acidosis, Respiratory; Adrenergic beta-2 Receptor Agonists; Adult; Albut | 2021 |
Implementation of a Critical Asthma Protocol in a Pediatric ICU.
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Humans; Intensive Car | 2021 |
Elevated Serum Lactate in Children With Status Asthmaticus Receiving Albuterol.
Topics: Albuterol; Bronchodilator Agents; Child; Humans; Intensive Care Units, Pediatric; Lactates; Status A | 2021 |
The effectiveness of magnesium sulfate for status asthmaticus outside the intensive care setting.
Topics: Adolescent; Albuterol; Bronchodilator Agents; Child; Child, Preschool; Cohort Studies; Critical Care | 2018 |
Effects of a PICU Status Asthmaticus De-Escalation Pathway on Length of Stay and Albuterol Use.
Topics: Albuterol; Bronchodilator Agents; Child; Critical Pathways; Female; Humans; Intensive Care Units, Pe | 2018 |
Variability Reduction-An Essential Aspect of Quality.
Topics: Albuterol; Child; Humans; Intensive Care Units, Pediatric; Length of Stay; Status Asthmaticus | 2018 |
Asthma Severity Pathway in the PICU.
Topics: Albuterol; Asthma; Humans; Intensive Care Units, Pediatric; Length of Stay; Retrospective Studies; S | 2018 |
Inflammatory and Comorbid Features of Children Admitted to a PICU for Status Asthmaticus.
Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists | 2018 |
Implementing a Respiratory Therapist-Driven Continuous Albuterol Weaning Protocol in the Pediatric ICU.
Topics: Albuterol; Bronchodilator Agents; Child; Clinical Protocols; Drug-Related Side Effects and Adverse R | 2019 |
A Respiratory Therapist-Driven Asthma Pathway Reduced Hospital Length of Stay in the Pediatric Intensive Care Unit.
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Clinical Protocols; C | 2019 |
Diastolic hypotension is an unrecognized risk factor for β-agonist-associated myocardial injury in children with asthma.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Biomarkers; Child; Child, Preschool; Cohort Studies; | 2013 |
Safety and effectiveness of continuous aerosolized albuterol in the non-intensive care setting.
Topics: Adolescent; Albuterol; Arrhythmias, Cardiac; Bronchodilator Agents; Child; Child, Preschool; Cohort | 2014 |
Effect of high-dose continuous albuterol nebulization on clinical variables in children with status asthmaticus.
Topics: Administration, Inhalation; Albuterol; Bronchodilator Agents; Child; Child, Preschool; Critical Care | 2015 |
If nothing goes wrong, is everything all right? Why we should be wary of zero numerators.
Topics: Albuterol; Bronchodilator Agents; Critical Care; Female; Humans; Male; Respiratory Therapy; Status A | 2015 |
Diastolic hypotension in pediatric patients with asthma receiving continuous albuterol.
Topics: Age Factors; Albuterol; Asthma; Blood Pressure; Bronchodilator Agents; Child; Child, Preschool; Dose | 2015 |
An Asthma Protocol Improved Adherence to Evidence-Based Guidelines for Pediatric Subjects With Status Asthmaticus in the Emergency Department.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Albuterol; Bronchodilator Agents; Child; Child, | 2015 |
Albuterol via metered-dose inhaler in children: Lower doses are effective, and higher doses are safe.
Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Pres | 2016 |
A Critical Asthma Standardized Clinical and Management Plan Reduces Duration of Critical Asthma Therapy.
Topics: Adolescent; Albuterol; Bronchodilator Agents; Child; Child, Preschool; Critical Care; Disease Manage | 2017 |
Acute severe asthma: new approaches to assessment and treatment.
Topics: Acute Disease; Adrenal Cortex Hormones; Albuterol; Anti-Asthmatic Agents; Asthma; Bronchodilator Age | 2009 |
Acute severe asthma: new approaches to assessment and treatment.
Topics: Acute Disease; Adrenal Cortex Hormones; Albuterol; Anti-Asthmatic Agents; Asthma; Bronchodilator Age | 2009 |
Acute severe asthma: new approaches to assessment and treatment.
Topics: Acute Disease; Adrenal Cortex Hormones; Albuterol; Anti-Asthmatic Agents; Asthma; Bronchodilator Age | 2009 |
Acute severe asthma: new approaches to assessment and treatment.
Topics: Acute Disease; Adrenal Cortex Hormones; Albuterol; Anti-Asthmatic Agents; Asthma; Bronchodilator Age | 2009 |
Case of reverse takotsubo cardiomyopathy in status asthmaticus.
Topics: Aged; Albuterol; Bronchodilator Agents; Echocardiography; Electrocardiography; Female; Humans; Nebul | 2010 |
Acute bronchial asthma.
Topics: Albuterol; Algorithms; Anti-Asthmatic Agents; Budesonide; Child; Child, Preschool; Diagnosis, Differ | 2011 |
Salbutamol: beware of the paradox!
Topics: Acidosis, Lactic; Albuterol; Blood Gas Analysis; Bronchodilator Agents; Child; Emergency Service, Ho | 2010 |
[Efficacy of treatment modification in status asthmaticus and complication frequency].
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Anti-Inflammatory Agents; Bronchodi | 2002 |
(R,S)-salbutamol plasma concentrations in severe asthma.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Bronchodilator Agents; Dose-Response Relations | 2003 |
Levalbuterol toxicity: no reason to be jittery.
Topics: Albuterol; Bronchodilator Agents; Child, Preschool; Humans; Male; Status Asthmaticus | 2003 |
A 10-year-old child with status asthmaticus, hypercapnia and a unilateral dilated pupil.
Topics: Albuterol; Bronchodilator Agents; Child; Humans; Hypercapnia; Ipratropium; Male; Mydriasis; Nebulize | 2005 |
Case records of the Massachusetts General Hospital. Case 15-2007. A 20-year-old woman with asthma and cardiorespiratory arrest.
Topics: Adrenergic beta-Agonists; Albuterol; Anti-Asthmatic Agents; Asthma; Cause of Death; Fatal Outcome; F | 2007 |
Anaphylaxis to salbutamol.
Topics: Adult; Albuterol; Anaphylaxis; Drug Hypersensitivity; Erythema; Female; Humans; Immunoglobulin E; Rh | 2008 |
Intravenous salbutamol in the treatment of status asthmaticus in children.
Topics: Adolescent; Adult; Albuterol; Asthma; Carbon Dioxide; Child; Child, Preschool; Drug Evaluation; Hear | 1984 |
Acute myopathy in status asthmaticus.
Topics: Acute Disease; Adult; Aged; Albuterol; Biopsy; Cohort Studies; Drug Therapy, Combination; Electromyo | 1993 |
Adenosine in the termination of albuterol-induced supraventricular tachycardia.
Topics: Adenosine; Albuterol; Child, Preschool; Humans; Male; Status Asthmaticus; Tachycardia, Supraventricu | 1994 |
Asthma requiring mechanical ventilation. A low morbidity approach.
Topics: Adult; Aerosols; Albuterol; Aminophylline; Combined Modality Therapy; Female; Humans; Hydrocortisone | 1994 |
Low-dose beta-agonist continuous nebulization therapy for status asthmaticus in children.
Topics: Administration, Inhalation; Adolescent; Aerosols; Albuterol; Child; Child, Preschool; Female; Humans | 1994 |
Efficacy and safety of continuous albuterol nebulization in children with severe status asthmaticus.
Topics: Administration, Inhalation; Adolescent; Albuterol; Child; Child, Preschool; Creatine Kinase; Humans; | 1996 |
[Acute myopathy in an asthmatic patient treated with corticoids and muscle relaxants in the intensive care unit].
Topics: Acute Disease; Administration, Topical; Albuterol; Anti-Inflammatory Agents; Beclomethasone; Critica | 1996 |
[Prognostic value and accuracy of crisis indicators in severe asthma].
Topics: Acute Disease; Albuterol; Blood Gas Monitoring, Transcutaneous; Bronchodilator Agents; Child; Child, | 1997 |
[Asthmatic crisis and spontaneous rupture of the esophagus].
Topics: Aged; Albuterol; Asthma; Bronchodilator Agents; Dexamethasone; Diagnosis, Differential; Esophageal D | 1998 |
Bronchodilator therapy in status asthmaticus.
Topics: Adrenergic beta-Agonists; Albuterol; Bronchodilator Agents; Drug Therapy, Combination; Humans; Iprat | 1999 |
Short-acting beta2-agonists.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Airway Obstruction; Albuterol; Asthma; Bro | 2000 |
Description of a delivery method for continuously aerosolized albuterol in status asthmaticus.
Topics: Adult; Aerosols; Albuterol; Asthma; Critical Care; Equipment Design; Humans; Male; Status Asthmaticu | 1990 |
An exaggerated response to beta-adrenergics.
Topics: Adrenergic beta-Agonists; Albuterol; Child; Humans; Isoetharine; Male; Metaproterenol; Neurologic Ex | 1989 |
Therapy of acute bronchospasm. Complicated by lactic acidosis and hypokalemia.
Topics: Acidosis, Lactic; Acute Disease; Albuterol; Bronchial Spasm; Child, Preschool; Drug Therapy, Combina | 1989 |
Acute asthma attack due to ophthalmic indomethacin.
Topics: Aged; Albuterol; Asthma; Combined Modality Therapy; Female; Glucocorticoids; Humans; Indomethacin; O | 1989 |
Comparison of beta-adrenergic agents delivered by nebulizer vs metered dose inhaler with InspirEase in hospitalized asthmatic patients.
Topics: Adult; Albuterol; Asthma; Female; Hospitalization; Humans; Male; Metaproterenol; Nebulizers and Vapo | 1988 |
[Asymptomatic electrical myocardial necrosis during the infusion of betamimetics in status asthmaticus].
Topics: Albuterol; Asthma; Cardiomyopathy, Dilated; Electrocardiography; Female; Humans; Middle Aged; Myocar | 1988 |
[Treatment of asthma crises in children with nebulized salbutamol].
Topics: Adolescent; Albuterol; Asthma; Child; Child, Preschool; Drug Evaluation; Female; Humans; Male; Nebul | 1988 |
Enhancement of theophylline clearance by intravenous albuterol.
Topics: Albuterol; Asthma; Drug Interactions; Humans; Infant; Infusions, Intravenous; Male; Metabolic Cleara | 1988 |
[Acute effect of intravenous salbutamol in status asthmaticus].
Topics: Adult; Albuterol; Asthma; Female; Hemodynamics; Humans; Infusions, Intravenous; Injections, Intraven | 1987 |
[Subcutaneous adrenaline versus inhaled salbutamol in the treatment of childhood asthmatic crisis].
Topics: Adolescent; Aerosols; Albuterol; Asthma; Child; Child, Preschool; Drug Evaluation; Epinephrine; Huma | 1987 |
[Treatment of acute crises of bronchial asthma in children using subcutaneous salbutamol as an alternative to adrenaline: comparative study].
Topics: Adolescent; Albuterol; Asthma; Child; Child, Preschool; Drug Evaluation; Epinephrine; Female; Heart | 1986 |
Relapse after single dose nebulised salbutamol in children with acute asthma.
Topics: Adolescent; Albuterol; Asthma; Child; Child, Preschool; Female; Humans; Male; Peak Expiratory Flow R | 1985 |
Intravenous vs. nebulized salbutamol for treatment of severe status asthmaticus.
Topics: Aerosols; Albuterol; Asthma; Humans; Infusions, Parenteral; Status Asthmaticus | 1985 |
Intravenous salbutamol for status asthmaticus.
Topics: Albuterol; Asthma; Child; Humans; Infusions, Parenteral; Status Asthmaticus | 1985 |